Welcome

 

Dear Industry Partner,

Increasing costs of modern medical modalities may generate substantial between interest of individuals and financial potential in a community.

At this Budapest meeting, cost-effectiveness of different liver diseases will be analysed by medical and health-economy experts to help physicians, insurance companies and decision makers in rational allocation of resources.
In addition to co-chairs professors Markus Peck-Radosavljevic (secretary general of EASL, Vienna, Austria) and Cihan Yurdaydin (educational councillor of EASL, Ankara, Turkey), other opinion leader hepatologist, including Professors Rafael Esteban (Barcelona, Spain), Graham Foster (London, UK),Christoph Sarrazin (Frankfurt, Germany) are invited to share their views on financial aspects of and cost-effectiveness in liver diseases.

Kind regards,

Dr. Horváth Gábor

Gabor Horvath, MD, (Budapest, Hungary)

CHAIR

TOPICS

Main topics include health benefit and cost-effectiveness of

arrow primary prevention (vaccination, diet, environmental factors)

arrow screening and surveillance (viral hepatitis, NAFLD, HCC)

arrow diagnostic algorithms (enzyme elevation, nodules, rare liver diseases)

arrow medical therapy (HCV, HBV, HCC, NFLD, NASH, cirrhosis etc.)

arrow surgical/invasive therapy (TIPS, RFA, transplantation)

arrow burden of liver diseases from scientific

MORE DETAILS>>

1. Cirrhosis
– Treatment choices of esophageal varices
– Diagnostic algorythm of liver nodules
– Somatostatin versus terlipressin in acute variceal bleeding – medical/surgical th.- TIPs vs. on-demand tap in refractory ascites / treatment modelling
– Screening versus non-screening for HCC in non-viral cirrhosis
2. HCV
– IFN-based/IFN-free treatment versus observation in CHC with F 1-2 fibrosis
– IFN-based/IFN-free treatment versus observation in CHC with F 3-4 fibrosis
– IFN-based/IFN-free treatment versus observation pre- during – post livertransplant
– Survillance versus no survillance in HCV cirrhosis regressed to F2/F3 from F4 after SVR
– Birth-cohort screening for HCV in Europe
– Screening for HCV in acute IVD population / HIV coinfected population
3. HBV
– Vaccination against HBV at birth versus at age 12
– Vaccination against HBV for older people
– Entecavir versus tenofovir in decompensated HBV cirrhosis

  • Entecarin versus tenofovir in compensated HBV cirrhosis
  • IFN versus NA for HBV in non-cirrhotic patients
  • Annual versus 6- monthly HBV-DNS on long term NA therapy

– Screening for HCC in decompensated or compensated HBV cirrhosis
– Screening for HCC in non- cirrhotic CHB on NA treatment

SCIENTIFIC ORGANIZING COMITTEE

 CHAIR

Gabor Horvath, MD
President, Hepatology Section of Hungarian Society of Gastroenterology
Budapest, Hungary

CO-CHAIRS

Prof. Cihan Yurdaydin, MD Prof. Bela Hunyady, MD Michael Makara, MD
Ankara, Turkey Kaposvár-Pécs, Hungary Budapest, Hungary

FACULTY

Prof. Geoffrey Dusheiko Prof. Jean-Michel Pawlotsky Prof. Robert Flisiak
London, UK Paris, France Bialystok, Poland
Ferenci-Peter
Krzysztof Łanda Prof. Peter Ferenci Prof. Livio Garattini
Vice Minister of Health, Poland Wien, Austria Ranica, Italy
Prof. Vladimir Zah Prof. Guenka Petrova Ken Redekop
Serbia Bulgaria Rotterdam, The Netherlands
Prof. Mojca Matičič Stanimir Hasurdjiev Prof. Vasily Isakov
Slovenia Bulgaria Moscow, Russia
Peter Jarcuska Prof. Krzysztof Tomasiewicz
Slovakia Poland

SPONSORS & PARTNERSHIP

Gold Sponsors

Abbvie
gilead

Bronze Sponsors

msd


Sponsors

  • ispor-logo
  • gaszroenerologiai-tarsasag-logo
  • kepes-hostess

To make this event possible

LOCATION & CONTACT

CONGRESS VENUE

Hilton Budapest

Hilton Budapest
1-3 Hess András square
1014 Budapest, Hungary

Phone: +36 1 889 6600
Fax: +36 1 889 6910
www.danubiushotels.hu/szallodak-budapest/hilton-budapest

ORGANISING SECRETARIAT

Medicongress Hungary Kft.

T: +36 30 275 11 81
F: +36 1 455 81 27
info@celdbudapest.eu
info@medicongressbudapest.com

© 2015 Medicongress Hungary Kft. All Rights Re­served. |